Hartland & Co. LLC Purchases 401 Shares of Eli Lilly and Company (LLY)

Hartland & Co. LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,787 shares of the company’s stock after purchasing an additional 401 shares during the quarter. Hartland & Co. LLC’s holdings in Eli Lilly and were worth $888,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Waldron LP increased its stake in shares of Eli Lilly and by 46.7% in the 1st quarter. Waldron LP now owns 4,948 shares of the company’s stock valued at $415,000 after acquiring an additional 1,574 shares during the last quarter. FTB Advisors Inc. increased its stake in shares of Eli Lilly and by 17.0% in the 1st quarter. FTB Advisors Inc. now owns 6,165 shares of the company’s stock valued at $516,000 after acquiring an additional 895 shares during the last quarter. Canandaigua National Bank & Trust Co. increased its stake in shares of Eli Lilly and by 3.3% in the 1st quarter. Canandaigua National Bank & Trust Co. now owns 9,569 shares of the company’s stock valued at $804,000 after acquiring an additional 306 shares during the last quarter. Confluence Wealth Management LLC increased its stake in shares of Eli Lilly and by 3.4% in the 1st quarter. Confluence Wealth Management LLC now owns 5,358 shares of the company’s stock valued at $451,000 after acquiring an additional 176 shares during the last quarter. Finally, Bbva Compass Bancshares Inc. increased its stake in shares of Eli Lilly and by 26.7% in the 1st quarter. Bbva Compass Bancshares Inc. now owns 7,770 shares of the company’s stock valued at $653,000 after acquiring an additional 1,636 shares during the last quarter. 75.72% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.86 earnings per share.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the transaction, the insider now owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 990,000 shares of company stock worth $82,949,650. 0.20% of the stock is owned by insiders.

A number of brokerages have recently commented on LLY. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. BMO Capital Markets upped their price target on Eli Lilly and from $71.00 to $73.00 and gave the company an “underperform” rating in a research note on Tuesday. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their price target for the company from $84.23 to $88.00 in a research note on Tuesday. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $88.57.

COPYRIGHT VIOLATION NOTICE: “Hartland & Co. LLC Purchases 401 Shares of Eli Lilly and Company (LLY)” was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/2956634/hartland-co-llc-purchases-401-shares-of-eli-lilly-and-company-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.